Peer-reviewed journal articles (5)
  1. 1. Ravon, F., Berns, E., Lambert, I., Rens, C., Adnet, P.-Y., Kiass, M., Megalizzi, V., Delporte, C., Baulard, A., Mathys, V., Boarbi, S., Wauthoz, N., & Fontaine, V. (2025). Assessment of Innovative Dry Powders for Inhalation of a Synergistic Combination Against Mycobacterium tuberculosis in Infected Macrophages and Mice. Pharmaceutics, 17(6), 705. doi:10.3390/pharmaceutics17060705
  2. 2. Ravon, F., Menchi, E., Lambot, C., Al Kattar, S., Chraibi, S., Remmelink, M., Fontaine, V., & Wauthoz, N. (2022). In vitro and in vivo local tolerability of a synergistic anti‐tuberculosis drug combination intended for pulmonary delivery. Journal of applied toxicology, 1-14. doi:10.1002/jat.4381
  3. 3. Zeng, S., Soetaert, K., Ravon, F., Vandeput, M., Bald, D., Kauffmann, J.-M., Mathys, V., Wattiez, R., & Fontaine, V. (2019). Isoniazid Bactericidal Activity Involves Electron Transport Chain Perturbation. Antimicrobial agents and chemotherapy, 63(3). doi:10.1128/AAC.01841-18
  4. 4. Sharbati, S., Ravon, F., Einspanier, R., & Bruegge, J. Z. (2019). Mycobacterium smegmatis but not mycobacterium avium subsp. Hominissuis causes increased expression of the long non-coding rna meg3 in thp-1-derived human macrophages and associated decrease of tgf-β. Microorganisms, 7(3), 63. doi:10.3390/microorganisms7030063
  5. 5. Zeng, S., Soetaert, K., Ravon, F., Vandeput, M., Bald, D., Kauffmann, J.-M., Mathys, V., Wattiez, R., & Fontaine, V. (2019). Isoniazid bactericidal activity involves electron transport chain perturbation. Antimicrobial agents and chemotherapy, 63(3), 1-20.
    6.   Papers published in national and international conferences or symposium proceedings (1)
  6. 1. Ravon, F., Menchi, E., Remmelink, M., Chraibi, S., Fontaine, V., & Wauthoz, N. (2022). In vitro and in vivo evaluations of the tolerance of a new and innovative anti-tuberculosis drug combination by inhalation. Abstracts from The Aerosol Society Drug Delivery to the Lungs 32. Vol. 35(35), A1-A20 (pp. 1-20) Drug Delivery to the Lungs(32: 8-10th December: Virtual). doi:10.1089/jamp.2022.ab01.abstracts
    7.   Active participation in international conferences and symposiums (1)
  7. 1. Ravon, F., Menchi, E., Remmelink, M., Chraibi, S., Fontaine, V., & Wauthoz, N. (2021). In vitro and in vivo evaluations of the tolerance of a new and innovative anti-tuberculosis drug combination by inhalation. Paper session presented at Drug Delivery to the Lung (32: 8-10th December 2021: Virtual).
    8.   Theses and master's dissertations (1)
  8. 1. Ravon, F. (2024). In vitro and in vivo evaluations of an innovative drug combination for pulmonary administration against tuberculosis (Unpublished doctoral dissertation). Université libre de Bruxelles, Faculté de Pharmacie, Bruxelles.